Is PT-141 prohibited in sport? WADA status

Athletes who encounter PT-141 (bremelanotide) online, whether through libido forums or bodybuilding communities, often ask the same question: does using it trigger a doping violation? The short answer is that bremelanotide does not appear by name on the current WADA Prohibited List^[1], but the answer is not as clean as that sentence makes it sound. This article explains why, and what athletes under WADA-governed sports need to verify before drawing any conclusions.

What PT-141 actually is

PT-141 is the research-code name for bremelanotide, a cyclic seven-amino-acid peptide that acts as a non-selective agonist of the melanocortin receptor family, with its strongest activity at MC4R and MC3R in the central nervous system. In June 2019 the FDA approved bremelanotide as Vyleesi (NDA 210557, Cosette Pharmaceuticals) for hypoactive sexual desire disorder in premenopausal women, dosed as a 1.75 mg subcutaneous injection as needed, up to eight times per month^[2]. The pivotal RECONNECT phase 3 programme (Kingsberg et al., 2019) provided the evidence base for that approval^[3]. No marketing authorisation exists in the EU, EEA, or UK; the EMA and MHRA have not approved bremelanotide. The grey-market 'PT-141' research vials athletes encounter online are not the approved Vyleesi product and carry none of the quality controls that apply to the FDA-approved formulation.

The WADA Prohibited List and where PT-141 sits

The WADA Prohibited List is organised into sections. Section S0, Non-Approved Substances, covers any pharmaceutical agent that has no marketing authorisation from any regulatory authority for human use. USADA confirmed this is the section where BPC-157 sits^[4]. Bremelanotide is not in S0, because Vyleesi holds FDA approval as an authorised human medicine.

Section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics, covers growth hormone, IGF-1, EPO, hCG, GHRH-releasing-factor analogues, and other listed peptide hormones. Critically, it also includes a catch-all provision: 'Any other growth factor or hormone' that is not explicitly named^[4]. Bremelanotide's mechanism, acting on melanocortin receptors in the central nervous system to modulate sexual desire, is distinct from the growth-factor and hormone axis that S2 primarily targets. It does not stimulate growth hormone release, erythropoiesis, or anabolic muscle pathways. No published anti-doping literature has classed bremelanotide under S2.

Named substance versus catch-all: why the distinction matters

The WADA list works in two ways. Some substances are prohibited because they are named explicitly, say sermorelin or hCG. Others are caught by broad categorical language, such as 'related substances' or 'any other substance with a similar chemical structure or similar biological effect.' An athlete who uses a substance not explicitly named but covered by a catch-all clause is still liable for a doping violation, regardless of whether they checked the list and found no mention of it.

The USADA guidance on peptides makes this explicit: athletes cannot rely on a substance being absent from the named list as a confirmation that it is permitted^[4]. The safe route is a formal check through GlobalDRO.com, which cross-references the current list against specific substances by country and sport, or a direct enquiry to USADA's Drug Reference Line (drugreference@USADA.org). Neither PeptideMethods.com nor any other third-party source can substitute for that check.

What the USADA enforcement record shows

No USADA enforcement action has been published naming bremelanotide or PT-141 as a prohibited substance. The enforcement cases that involve peptides have centred on substances that are either explicitly listed (hGH, EPO, hCG) or fall under the S0 non-approved-substance catch-all (BPC-157, TB-500, certain GHRH analogues). A GLP-1 agonist precedent is instructive: USADA confirmed in 2024 that GLP-1 receptor agonists such as semaglutide are 'not prohibited in sport,' even while WADA monitors their use for potential future listing^[5]. Bremelanotide, as an FDA-approved receptor agonist with no known performance-enhancement pathway in trained athletes, sits in a similar regulatory posture: not on the list, not the subject of a known enforcement action, but not formally cleared either.

What athletes actually need to do

Athletes subject to the WADA Code should treat the absence of a substance from a named-substance list as the beginning of the enquiry, not the end of it. The four practical steps are: check GlobalDRO.com for your sport and country; contact USADA's Drug Reference Line if GlobalDRO returns an ambiguous result; consider whether the substance falls under any catch-all clause in the section most relevant to its mechanism; and, if in doubt, avoid the substance until you have a written confirmation from your national anti-doping authority.

Grey-market PT-141 vials sold as research chemicals introduce a separate risk: product contamination. A vial labelled 'PT-141' could contain a different peptide, an analogue that is explicitly prohibited, or a mislabelled dose. USADA has documented contamination cases where athletes tested positive for substances they did not knowingly use, and strict-liability rules mean that intent is not a defence in doping cases. The PT-141 page on this site covers the FDA-approved product versus grey-market sourcing distinction in detail.

What we do not know

Whether WADA will add bremelanotide or melanocortin receptor agonists to a future Prohibited List has not been publicly signalled. WADA has stated it monitors substances for possible listing when two of three criteria are met: potential to enhance performance, a health risk to athletes, or a violation of the spirit of sport. Bremelanotide has not been shown to enhance athletic performance in trained athletes, and no application for listing has been publicly disclosed. That picture could change if research identifies a performance pathway, but as of June 2026, no such signal is in the public literature.

If you are subject to doping testing and are considering bremelanotide for any reason, including its FDA-approved HSDD indication, take the question to your prescribing clinician and your national anti-doping authority before use. For the regulatory and approval status by country, see the PT-141 peptide page on this site.